GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » Other Current Assets

Veritas In Silico (TSE:130A) Other Current Assets : 円24.3 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Veritas In Silico Other Current Assets?

Veritas In Silico's other current assets for the quarter that ended in Dec. 2024 was 円24.3 Mil.

Veritas In Silico's quarterly other current assets increased from Mar. 2024 (円5.3 Mil) to Jun. 2024 (円17.9 Mil) and increased from Jun. 2024 (円17.9 Mil) to Dec. 2024 (円24.3Mil).

Veritas In Silico's annual other current assets declined from Dec. 2022 (円10.9 Mil) to Dec. 2023 (円4.7 Mil) increased from Dec. 2023 (円4.7 Mil) to Dec. 2024 (円24.3 Mil).


Veritas In Silico Other Current Assets Historical Data

The historical data trend for Veritas In Silico's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veritas In Silico Other Current Assets Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Other Current Assets
19.05 10.93 4.71 24.35

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24
Other Current Assets Get a 7-Day Free Trial 15.03 4.71 5.28 17.85 24.35

Veritas In Silico Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Veritas In Silico Other Current Assets Related Terms

Thank you for viewing the detailed overview of Veritas In Silico's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Veritas In Silico Business Description

Traded in Other Exchanges
N/A
Address
1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.

Veritas In Silico Headlines

No Headlines